{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:54:22Z","timestamp":1784836462487,"version":"3.55.0"},"reference-count":28,"publisher":"Informa UK Limited","issue":"7","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Takeda Development Center Americas, Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2026,3,16]]},"DOI":"10.1080\/14796694.2025.2609296","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T13:51:11Z","timestamp":1768225871000},"page":"843-852","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Matching-adjusted indirect treatment comparison of A+AVD vs PET-guided ABVD in newly diagnosed advanced Hodgkin lymphoma"],"prefix":"10.1080","volume":"22","author":[{"given":"Fjoralba","family":"Kristo","sequence":"first","affiliation":[{"name":"Takeda Development Center Americas, Inc","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Molinari","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals America, Inc","place":["Lexington, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"Lan","sequence":"additional","affiliation":[{"name":"Cytel Inc","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Paly","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals America, Inc","place":["Lexington, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramsha","family":"Khan","sequence":"additional","affiliation":[{"name":"Cytel Inc","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbey","family":"Poirier","sequence":"additional","affiliation":[{"name":"Cytel Inc","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoora","family":"Moradian","sequence":"additional","affiliation":[{"name":"Cytel Inc","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin N","family":"Savani","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Zomas","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajibade","family":"Ashaye","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"e_1_3_11_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01281-9"},{"key":"e_1_3_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16587"},{"key":"e_1_3_11_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.24.00277"},{"key":"e_1_3_11_6_1","unstructured":"National Cancer Institute. SEER*Explorer: an interactive website for seer cancer statistics [internet]. Surveillance research program. [cited 2024 Sep]. Available from: https:\/\/seer.cancer.gov\/explorer\/"},{"key":"e_1_3_11_7_1","unstructured":"National Comprehensive Cancer Network. Hodgkin lymphoma version 1. 2025 [cited 2025 Jan]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hodgkins.pdf"},{"key":"e_1_3_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115073"},{"key":"e_1_3_11_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy080"},{"key":"e_1_3_11_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708984"},{"key":"e_1_3_11_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206125"},{"key":"e_1_3_11_12_1","unstructured":"U.S. Food and Drug Administration. Highlights of prescribing information. ADCETRIS\u00ae (brentuximab vedotin) for injection for intravenous use Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/125388s107lbl.pdf"},{"key":"e_1_3_11_13_1","unstructured":"Takeda. European Commission approves ADCETRIS\u00ae (brentuximab vedotin) for the treatment of adult patients with Previously untreated CD30+ stage iii Hodgkin lymphoma in combination with AVD. 2023 Oct 18 [cited 2025 Jan]. Available from: https:\/\/www.takeda.com\/newsroom\/newsreleases\/2023\/european-commission-approves-adcetris-brentuximab-vedotin-for-the-treatment-of-adult-patients-with-previously-untreated-cd30-stage-iii-hodgkin-lymphoma-in-combination-with-avd\/"},{"key":"e_1_3_11_14_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2022.10.006"},{"key":"e_1_3_11_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000719"},{"key":"e_1_3_11_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01177"},{"key":"e_1_3_11_17_1","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2014.053"},{"key":"e_1_3_11_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392104"},{"key":"e_1_3_11_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2014.001457"},{"key":"e_1_3_11_20_1","unstructured":"Mitchell M Muftakhidinov B Winchen T. Engauge digitizer software 2023. Available from: http:\/\/markummitchell.github.io\/engauge-digitizer"},{"key":"e_1_3_11_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9"},{"key":"e_1_3_11_22_1","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2022","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna, Austria. Available from R Foundation for Statistical Computing; 2022. Available from: https:\/\/www.R-project.org\/"},{"key":"e_1_3_11_23_1","unstructured":"Phillippo D Ades T Dias S et al. Nice DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to nice. 2016."},{"key":"e_1_3_11_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-021-04379-2"},{"key":"e_1_3_11_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510093"},{"key":"e_1_3_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01315-1"},{"key":"e_1_3_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.07.014"},{"key":"e_1_3_11_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1793666"},{"key":"e_1_3_11_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3298"},{"key":"e_1_3_11_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X17725740"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2609296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:21:20Z","timestamp":1773757280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2025.2609296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,3,16]]}},"alternative-id":["10.1080\/14796694.2025.2609296"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2025.2609296","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-09-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}